Scholars Central

Conference abstractPublished 18 Nov 2014

Involvement of PKR in Alzheimer�s disease

Authors: Jacques Hugon, Julien Dumurgier, Fran�ois Mouton-Liger, Pauline Lapalus, Magali Prevot, Sandrine Indart, Jean Louis Laplanche, Claire Paquet

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Alzheimer�s disease (AD) is neuropathologically characterized by senile plaques made of Aβ 1-42 peptide, neurofibrillary tangles composed by hyperphosphorylated tau protein and synaptic and neuronal losses. Aβ 1-42 is known to induce neuronal death. PKR is a pro-apoptotic kinase that can phosphorylate the initiation factor eIF2α and reduce protein translation. The activation of PKR is induced by virus, cytokines, calcium, and Aβ 1-42. PKR can also modulate inflammation and the genetic knock down of PKR improves memory in experimental mice. Author�s group has been working on PKR for the last years and we have shown that activated PKR accumulates in the degenerating neurons of AD patients and that PKR can experimentally control the expression of the APP cleaving enzyme BACE1, reduce the production of Aβ peptide and indirectly induce in neuronal cell cultures the phosphorylation of tau protein. In a recent study we have analyzed CSF levels of PKR and activated PKR (pPKR) in AD patients compared to neurological controls and patients with amnestic Mild Cognitive Impairment (MCI). The CSF of 45 AD patients, 11 patients with Mild Cognitive Impairment and 35 neurological controls were assessed and the patients were followed for more than 2 years. CSF levels of Aβ 1-42, Tau, pTau, PKR and pPKR were evaluated. Cognitive assessments were carried out twice a year. All patients or care givers gave their written inform consents. The mean CSF pPKR level was increased (300%) in AD patients compared to neurological disease controls. The sensitivity was 91.1% and the specificity was 94.3%. Many MCI patients had also increased pPKR concentrations. In AD patients PKR and pPKR levels correlate with pTau levels and with the cognitive decline assessed by MMSE over more than 2 years. In conclusion, experimental and clinical data suggests that pPKR is detrimental to the formation of memory and that this activated kinase interferes with the abnormal molecular pathways and the clinical evolution of the disease. PKR represents a possible new biomarker and pharmacological target in AD.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Alzheimers Disease & Parkinsonism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Alzheimers Disease & Parkinsonism
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Jacques Hugon”
  • BylineArticles whose byline prints “Julien Dumurgier”
  • BylineArticles whose byline prints “Fran�ois Mouton-Liger”
  • BylineArticles whose byline prints “Pauline Lapalus”
  • BylineArticles whose byline prints “Magali Prevot”
  • BylineArticles whose byline prints “Sandrine Indart”
  • BylineArticles whose byline prints “Jean Louis Laplanche”
  • BylineArticles whose byline prints “Claire Paquet”